172 related articles for article (PubMed ID: 33311990)
21. Remarkable response to alectinib for metastatic papillary thyroid cancer with STRN-ALK fusion: A case report.
Zhu L; Ma S; Xia B
Front Oncol; 2022; 12():1009076. PubMed ID: 36439495
[TBL] [Abstract][Full Text] [Related]
22. Case report: Two novel
Liao S; Sun H; Wu J; Lu H; Fang Y; Wang Y; Liao W
Front Oncol; 2022; 12():916315. PubMed ID: 35941871
[TBL] [Abstract][Full Text] [Related]
23. Novel HIVEP1-ALK fusion in a patient with lung adenocarcinoma demonstrating sensitivity to alectinib: a case report.
Gu X; Wang W; Wu W; Zhang Y; Shao L; Santarpia M; Christopoulos P; Myall NJ; Shi Z; Lou G
Transl Lung Cancer Res; 2022 May; 11(5):902-909. PubMed ID: 35693284
[TBL] [Abstract][Full Text] [Related]
24. Transformation of NSCLC to SCLC harboring EML4-ALK fusion with V1180L mutation after alectinib resistance and response to lorlatinib: A case report and literature review.
Lingling X; Maoxi C; Wei Y; Jieting Z; Yuanyuan Y; Ning X
Lung Cancer; 2023 Dec; 186():107415. PubMed ID: 37907052
[TBL] [Abstract][Full Text] [Related]
25. Feasibility and Safety of Neoadjuvant Alectinib in Pulmonary Invasive Mucinous Adenocarcinoma with ALK Rearrangement: Case Report and Literature Review.
Gu R; Shi Z; Duan T; Song M
Onco Targets Ther; 2021; 14():5107-5113. PubMed ID: 34707369
[TBL] [Abstract][Full Text] [Related]
26. Neoadjuvant alectinib in locally advanced lung adenocarcinoma with anaplastic lymphoma kinase rearrangement: case series and literature review.
Wang Z; Wu R; Li C; Cheng K; Di Y; Lv T; Liu H; Song Y
Anticancer Drugs; 2023 Nov; 34(10):1069-1075. PubMed ID: 36688904
[TBL] [Abstract][Full Text] [Related]
27. A novel alectinib-sensitive CTNND1-ALK fusion in a lung adenocarcinoma patient: a case report.
Tian X; Liao Q; Yang Q; Chen L; Xiao M; Cheng Y
Invest New Drugs; 2022 Aug; 40(4):850-853. PubMed ID: 35441911
[TBL] [Abstract][Full Text] [Related]
28. STK3-ALK, a Novel ALK Rearrangement in Non-Small Cell Lung Cancer With Sensitivity to Tyrosine Kinase Inhibitors: A Case Report.
Feng C; Zhou R; Liu F; Wang T; Liu S; Shao Y
Front Oncol; 2021; 11():700341. PubMed ID: 34490099
[TBL] [Abstract][Full Text] [Related]
29. Coexistence of a novel NBEA-ALK, EML4-ALK double-fusion in a lung adenocarcinoma patient and response to alectinib: A case report.
Liang Q; Xu H; Liu Y; Zhang W; Sun C; Hu M; Zhu Y; Tan S; Xu X; Wang S; Liu L
Lung Cancer; 2021 Dec; 162():86-89. PubMed ID: 34763158
[TBL] [Abstract][Full Text] [Related]
30. Effective treatment in lung adenocarcinoma patient with brain metastases harboring novel CLHC1/RNT4 intergenic region- ALK fusion: A case report.
Xia H; Liang B; Liu G; Qi Y; Luo N; Li M
Medicine (Baltimore); 2022 Apr; 101(14):e29134. PubMed ID: 35446297
[TBL] [Abstract][Full Text] [Related]
31. Clinical Impact of Switching to Ceritinib After Severe AEs Related to Crizotinib/Alectinib in a Novel
Shen G; Du Y; Shen J; Zhang J; Xia X; Huang M; Shen W
Onco Targets Ther; 2021; 14():5471-5475. PubMed ID: 34992382
[TBL] [Abstract][Full Text] [Related]
32. Genomic Signature of Driver Genes Identified by Target Next-Generation Sequencing in Chinese Non-Small Cell Lung Cancer.
Wen S; Dai L; Wang L; Wang W; Wu D; Wang K; He Z; Wang A; Chen H; Zhang P; Dong X; Dong YA; Wang K; Yao M; Wang M
Oncologist; 2019 Nov; 24(11):e1070-e1081. PubMed ID: 30902917
[TBL] [Abstract][Full Text] [Related]
33. Dramatic response to alectinib in a lung adenocarcinoma patient harboring a Novel SSFA2-ALK fusion.
Lin X; Yang X; Tan Y; Duan Q; He M
Invest New Drugs; 2022 Oct; 40(5):1160-1163. PubMed ID: 35608716
[TBL] [Abstract][Full Text] [Related]
34.
Sun N; Zhuang Y; Zhang J; Chen S; Dai Y; Guo R
Onco Targets Ther; 2021; 14():5161-5166. PubMed ID: 34729013
[TBL] [Abstract][Full Text] [Related]
35. Case Report: A rare case of non-small cell lung cancer with STRN-ALK fusion in a patient in very poor condition treated with first-line ensartinib.
Song GQ; Li YZ; Kong W; Hu GQ
Front Oncol; 2023; 13():1235679. PubMed ID: 37810968
[TBL] [Abstract][Full Text] [Related]
36. Lung adenocarcinoma with brain metastasis detected dual fusion of LOC399815-ALK and ALK-EML4 in combined treatment of Alectinib and CyberKnife: A case report.
Li Y; Lu S; Yao P; Huang W; Huang Y; Zhou Y; Yuan Y; Cheng S; Wu F
Medicine (Baltimore); 2024 Jan; 103(3):e36992. PubMed ID: 38241569
[TBL] [Abstract][Full Text] [Related]
37. Combinatorial therapy is a safe and durable treatment option in
Jang C; Sabari J
Transl Lung Cancer Res; 2023 Dec; 12(12):2558-2564. PubMed ID: 38205199
[TBL] [Abstract][Full Text] [Related]
38. Response to ALK-TKIs in a lung adenocarcinoma patient harboring dual DCTN1-ALK and ALK-CLIP4 rearrangements.
Gao F; Gao F; Wu H; Lu J; Xu Y; Zhao Y
Thorac Cancer; 2022 Apr; 13(7):1088-1090. PubMed ID: 35212154
[TBL] [Abstract][Full Text] [Related]
39. Identification of triple gene fusion ALK-LRRN2, LTBP1-ALK, and HIP1-ALK in advanced lung adenocarcinoma and response to alectinib: A case report.
Ning S; Shi C; Zhang H; Li J
Medicine (Baltimore); 2021 Dec; 100(51):e27999. PubMed ID: 34941039
[TBL] [Abstract][Full Text] [Related]
40. First case report of a novel KIF13A-ALK fusion in a lung adenocarcinoma patient and response to alectinib with a 4-year follow-up.
Mo Z; Cai C; Yao J; Zhao J; Zhang M; Liu H; Mu X
Front Genet; 2023; 14():1289346. PubMed ID: 38155713
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
